MA39983A - Dérivés de carboxamide - Google Patents

Dérivés de carboxamide

Info

Publication number
MA39983A
MA39983A MA039983A MA39983A MA39983A MA 39983 A MA39983 A MA 39983A MA 039983 A MA039983 A MA 039983A MA 39983 A MA39983 A MA 39983A MA 39983 A MA39983 A MA 39983A
Authority
MA
Morocco
Prior art keywords
carboxamide derivatives
present
relates
compounds
manufacture
Prior art date
Application number
MA039983A
Other languages
English (en)
Other versions
MA39983B1 (fr
Inventor
Mahbub Ahmed
Kamlesh Jagdis Bala
Andrew Brearley
Anne-Marie D'souza
James Dale
David Porter
Robert Alexander Pulz
Lisa Ann Rooney
David Andrew Sandham
Duncan Shaw
Nichola Smith
Jessica Louise Taylor
Roger John Taylor
Thomas Josef Troxler
Joe Wrigglesworth
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50735903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39983(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA39983A publication Critical patent/MA39983A/fr
Publication of MA39983B1 publication Critical patent/MA39983B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne un composé de formule (i) ou un sel pharmaceutiquement acceptable de celui-ci; un procédé de fabrication de composés de l'invention et leurs utilisations thérapeutiques. La présente invention concerne, en outre, une combinaison de principes pharmacologiquement actifs et une composition pharmaceutique.
MA39983A 2014-05-14 2015-05-14 Dérivés de carboxamide MA39983B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14168303 2014-05-14
PCT/US2015/030817 WO2015175796A1 (fr) 2014-05-14 2015-05-14 Dérivés de carboxamide

Publications (2)

Publication Number Publication Date
MA39983A true MA39983A (fr) 2017-03-22
MA39983B1 MA39983B1 (fr) 2021-05-31

Family

ID=50735903

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39983A MA39983B1 (fr) 2014-05-14 2015-05-14 Dérivés de carboxamide

Country Status (38)

Country Link
US (6) US9403810B2 (fr)
EP (1) EP3143018B1 (fr)
JP (1) JP6523338B2 (fr)
KR (3) KR20260023080A (fr)
CN (1) CN106661012B (fr)
AP (1) AP2016009550A0 (fr)
AR (1) AR100440A1 (fr)
AU (1) AU2015259083B2 (fr)
BR (1) BR112016026552B1 (fr)
CA (1) CA2948543C (fr)
CL (1) CL2016002839A1 (fr)
CR (1) CR20160527A (fr)
CU (1) CU24434B1 (fr)
CY (1) CY1124251T1 (fr)
DK (1) DK3143018T3 (fr)
EA (1) EA030938B1 (fr)
ES (1) ES2874882T3 (fr)
HR (1) HRP20210783T1 (fr)
HU (1) HUE054590T2 (fr)
IL (1) IL248785B (fr)
JO (1) JO3610B1 (fr)
LT (1) LT3143018T (fr)
MA (1) MA39983B1 (fr)
MX (1) MX374383B (fr)
MY (1) MY186598A (fr)
PE (1) PE20171443A1 (fr)
PH (1) PH12016502246A1 (fr)
PL (1) PL3143018T3 (fr)
PT (1) PT3143018T (fr)
RS (1) RS61874B1 (fr)
SG (1) SG11201609217UA (fr)
SI (1) SI3143018T1 (fr)
SV (1) SV2016005313A (fr)
TN (1) TN2016000489A1 (fr)
TW (2) TWI714528B (fr)
UY (1) UY36124A (fr)
WO (1) WO2015175796A1 (fr)
ZA (1) ZA201607658B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403810B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
US9403833B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
CA3081424A1 (fr) * 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Composes spirocycliques a utiliser en tant que modulateurs du recepteur farnesoide x
CN108689976B (zh) * 2018-07-23 2021-12-28 陕西师范大学 5-磺基水杨酸协同二氯二茂钛催化合成4-碘代四氢吡喃衍生物的方法
IL299680A (en) * 2020-07-09 2023-03-01 Bristol Myers Squibb Co Pyrazolone formyl peptide 2 receptor agonists
JP2023541601A (ja) 2020-09-10 2023-10-03 プレシリックス・ナームローゼ・ベンノートシヤープ Ｆａｐに対する抗体フラグメント
WO2023203135A1 (fr) 2022-04-22 2023-10-26 Precirix N.V. Anticorps radiomarqué amélioré
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
WO2024242594A1 (fr) * 2023-05-23 2024-11-28 Общество С Ограниченной Ответственностью "Ифар" Agent de traitement d'hypertensions pulmonaires

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2655009A1 (de) 1976-12-04 1978-06-15 Hoechst Ag Isoxazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
EP1192174A4 (fr) * 1999-06-11 2002-08-28 Univ New York State Res Found Antagonistes des voies de signalisation bmp et tgf beta
US7354722B1 (en) 1999-06-11 2008-04-08 Signal Pharmaceuticals Modulators of Smurf and BMP/TGFβ signaling pathways
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
GB0312368D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel ureido- and amido-pyrazolone derivatives
EP1667983A4 (fr) 2003-09-23 2010-07-21 Merck Sharp & Dohme Modulateurs pyrazole de recepteurs de glutamate metabotropiques
US7291743B2 (en) 2005-03-29 2007-11-06 Geneblue Corporation Isoxazole derivatives and methods of treating nitric oxide mediated diseases
WO2008121861A2 (fr) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Composés à base de pyrazole et de pyrrole utiles dans le traitement de troubles du métabolisme du fer
WO2009011850A2 (fr) 2007-07-16 2009-01-22 Abbott Laboratories Nouveaux composés thérapeutiques
JP2011511756A (ja) 2007-08-02 2011-04-14 ナームローゼ・フエンノートチヤツプ・オルガノン Ｔｒｐｖ１モジュレータとしての５−フェニル−イソオキサゾール−３−カルボキサミド誘導体
US8293757B2 (en) 2007-08-22 2012-10-23 Irm Llc 5-(4-(haloalkoxy)phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
WO2009086303A2 (fr) * 2007-12-21 2009-07-09 University Of Rochester Procédé permettant de modifier la durée de vie d'organismes eucaryotes
WO2011151361A1 (fr) 2010-06-03 2011-12-08 Glaxo Group Limited Nouveaux composés
CA2823877C (fr) 2011-02-18 2020-01-07 Idorsia Pharmaceuticals Ltd Nouveaux derives de pyrazole et d'imidazole utiles a titre d'antagonistes d'orexine
US9403810B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
US9403833B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
KR20170002623A (ko) 2014-05-14 2017-01-06 화이자 인코포레이티드 피라졸로피리딘 및 피라졸로피리미딘
US20170088546A1 (en) * 2014-05-14 2017-03-30 Novartis Ag Carboxamide inhibitors

Also Published As

Publication number Publication date
AU2015259083A1 (en) 2016-11-24
SG11201609217UA (en) 2016-12-29
CY1124251T1 (el) 2022-07-22
ZA201607658B (en) 2017-09-27
JP2017515853A (ja) 2017-06-15
US20190381011A1 (en) 2019-12-19
BR112016026552A8 (pt) 2021-07-06
AP2016009550A0 (en) 2016-11-30
AR100440A1 (es) 2016-10-05
CU24434B1 (es) 2019-09-04
CR20160527A (es) 2017-04-28
JO3610B1 (ar) 2020-08-27
US11672782B2 (en) 2023-06-13
IL248785B (en) 2020-04-30
US20200268718A1 (en) 2020-08-27
EA030938B1 (ru) 2018-10-31
TWI714528B (zh) 2021-01-01
US20230301970A1 (en) 2023-09-28
CN106661012B (zh) 2019-12-20
CA2948543C (fr) 2022-08-16
MY186598A (en) 2021-07-29
KR102534033B1 (ko) 2023-05-19
CA2948543A1 (fr) 2015-11-19
NZ725918A (en) 2023-09-29
EP3143018B1 (fr) 2021-03-10
TW201946921A (zh) 2019-12-16
BR112016026552B1 (pt) 2023-02-14
US20170014388A1 (en) 2017-01-19
MX2016014939A (es) 2017-02-28
EP3143018A1 (fr) 2017-03-22
AU2015259083B2 (en) 2017-09-14
DK3143018T3 (da) 2021-05-31
US20150329529A1 (en) 2015-11-19
TN2016000489A1 (en) 2018-04-04
BR112016026552A2 (pt) 2017-08-15
UY36124A (es) 2016-01-08
US9403810B2 (en) 2016-08-02
US20210052554A1 (en) 2021-02-25
US10195181B2 (en) 2019-02-05
RS61874B1 (sr) 2021-06-30
IL248785A0 (en) 2017-01-31
MX374383B (es) 2025-03-06
SV2016005313A (es) 2018-06-12
SI3143018T1 (sl) 2021-08-31
KR20260023080A (ko) 2026-02-20
JP6523338B2 (ja) 2019-05-29
WO2015175796A1 (fr) 2015-11-19
LT3143018T (lt) 2021-06-10
CL2016002839A1 (es) 2017-01-27
PE20171443A1 (es) 2017-09-29
PT3143018T (pt) 2021-06-01
HRP20210783T1 (hr) 2021-06-25
HUE054590T2 (hu) 2021-09-28
CU20160166A7 (es) 2017-03-03
KR20170003666A (ko) 2017-01-09
PL3143018T3 (pl) 2021-08-30
PH12016502246B1 (en) 2017-01-09
EA201692300A1 (ru) 2017-04-28
PH12016502246A1 (en) 2017-01-09
TW201623296A (zh) 2016-07-01
ES2874882T3 (es) 2021-11-05
CN106661012A (zh) 2017-05-10
MA39983B1 (fr) 2021-05-31
KR20230074827A (ko) 2023-05-31

Similar Documents

Publication Publication Date Title
MA39983B1 (fr) Dérivés de carboxamide
MA37834A1 (fr) Analogues de pyridazine 1,4-disubstituée et procédés de traitement de troubles liés à une déficience en smn
MA37477A1 (fr) Modulateurs des voies du complément et leurs utilisations
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MA34837B1 (fr) Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla)
MA46337B1 (fr) Composé de pyridine
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
MA35275B1 (fr) Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5a
MX391812B (es) Agonista fxr derivado de esteroides.
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
MA37405A1 (fr) Composés hétérocyclyle
PH12018500061A1 (en) Oxysterols and methods of use thereof
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
MA38330B1 (fr) Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre)
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
NZ746906A (en) Oxaborole esters and uses thereof
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
MX2016014946A (es) Derivados de carboxamida.
EA202091481A1 (ru) Замещенные алкиниленовые соединения в качестве противораковых агентов
NZ764463A (en) Heterocyclic compound and application thereof in medicine
MA37872A1 (fr) Sels de composé benzothiazolone utilisés en tant qu'agoniste de beta-2-adrenoceptor